Table 5.
Serum MMPs/TIMPs and SDF-1α changes in the ALT improved group and ALT uncontrolled group
| Weeks |
|||||
|---|---|---|---|---|---|
| 0 | 21 | 35 | 70 | ||
| ALT improved group (n=8) | ALT (IU/L) | 54.9±35.4 | 26.0±9.8 | 34.3±13.2 | 25.3±12.9 |
| MMP-1 (ng/mL) | 2,404.2±2,230.8 | 1,805.9±1366.4 | 743.9±582.6 | 828.1±594.5 | |
| MMP-2 (ng/mL) | 36.4±12.4 | 26.0±14.5 | 36.0±16.0 | 36.0±3.9 | |
| MMP-9 (ng/mL) | 33.5±37.3 | 12.2±9.2 | 34.0±16.0 | 34.0±5.2 | |
| TIMP-1 (ng/mL) | 131.9±25.3 | 122.6±16.0 | 132.0±7.2 | 132.0±37.5 | |
| TIMP-2 (ng/mL) | 60.7±8.9 | 73.5±5.0 | 61.0±7.3 | 61.0±2.1 | |
| SDF-1α (pg/mL) | 313.5±222.6 | 325.9±113.8 | 314.0±57.1 | 314.0±145.4 | |
| ALT uncontrolled group (n=7) | ALT (IU/L) | 80.4±29.4 | 49.8±23.4 | 48.3±20.0 | 72.3±26.7 |
| MMP-1 (ng/mL) | 1,387.1±877.0 | 1,453.0±1,198.6 | 1,059.0±761.9 | 962.3±794.8 | |
| MMP-2 (ng/mL) | 28.0±6.9 | 32.3±25.9 | 22.5±8.0 | 36.8±16.0 | |
| MMP-9 (ng/mL) | 32.4±19.3 | 21.9±15.5 | 11.6±2.8 | 41.1±29.7 | |
| TIMP-1 (ng/mL) | 126.9±16.1 | 147.3±20.5 | 118.9±10.0 | 158.4±16.0 | |
| TIMP-2 (ng/mL) | 54.9±16.3 | 81.0±9.3 | 60.7±17.6 | 78.7±11.5 | |
| SDF-1α (pg/mL) | 135.2±71.6 | 365.5±211.3 | 135.0±34.5 | 464.2±338.2 | |
Values indicate mean ± standard deviation (SD). No statistical significance between the two groups in serum levels of ALT, MMPs/TIMPs at 0, 21, 35 and 70 weeks.
MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; SDF, stromal cell-derived factor; ALT, alanine aminotransferase.